Key Insights

Highlights

Success Rate

71% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 72/100

Termination Rate

13.3%

2 terminated out of 15 trials

Success Rate

71.4%

-15.1% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed with results

Key Signals

1 with results71% success

Data Visualizations

Phase Distribution

10Total
Not Applicable (8)
P 1 (2)

Trial Status

Completed5
Recruiting2
Not Yet Recruiting2
Terminated2
Unknown2
Enrolling By Invitation1

Trial Success Rate

71.4%

Benchmark: 86.5%

Based on 5 completed trials

Clinical Trials (15)

Showing 15 of 15 trials
NCT07359183RecruitingPrimary

A Long Term, Observational Follow-Up Study of Children and Young People Who Underwent an 18-Month Course of Oral Immunotherapy Treatment for Peanut, Egg or Milk Allergy (5-15 Years Post-Treatment)

NCT07265648Completed

Assessing Diet, Stress Scores, and Other Health Metrics in Healthy Northern California Adults

NCT06751810Not ApplicableCompletedPrimary

Nutritional Status in Children With Food Allergy: Evaluation of a New Supplement

NCT07073404Not Yet RecruitingPrimary

Omalizumab for Plant-Food Allergy Due to Sensitization to LTP or Profilin

NCT06997432Not Yet RecruitingPrimary

Endophenotyping for Plant-based Food Allergy Diagnosis, Tolerance Biomarkers, and Mechanisms in Microneedle Immunotherapy

NCT06947252Not ApplicableEnrolling By Invitation

Frequency of Food Allergy Confirm by Oral Food Challenge Among Foods Avoidance in Atopic Dermatitis Children

NCT06916819Not ApplicableRecruitingPrimary

Food Challenge at Home or in Medical Practice - the FoodCHOMP Study

NCT02286999Phase 1Withdrawn

Probiotic Supplementation in Breastfed Newborn Infants

NCT01631591Completed

Prevalence of Food Allergies in a Cohort of Adult Patients With Eosinophilic Esophagitis

NCT00736281Not ApplicableTerminatedPrimary

Sublingual Immunotherapy for Food Allergy

NCT01577628Not ApplicableTerminated

Daily Use of Lipikar Balm AP From Birth in Infants at High Risk of Developing Atopic Dermatitis

NCT02384707Not ApplicableUnknownPrimary

Master Allergen Child Nutrition. Reintroduction of Small Doses

NCT02208414Not ApplicableUnknownPrimary

Randomized Double-Blind Placebo-Controlled Crab or Shrimp Allergy Reduction Study Using Nambudripad Allergy Elimination Techniques

NCT00247156Phase 1Completed

An Autism Study Using Nambudripad's Food Allergy Elimination Treatments

NCT00277407Not ApplicableCompleted

Treatment of Autistic Children Using NAET Procedures

Showing all 15 trials

Research Network

Activity Timeline